search
Back to results

Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract

Primary Purpose

Osteoarthritis, Knee

Status
Withdrawn
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Enteric coated Devil's Claw
Non-enteric coated Devil's Claw
Sponsored by
University of Missouri-Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Osteoarthritis, Knee

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:- adult (at least 18 years of age);

  • diagnosed with knee osteoarthritis (OA) ;
  • body mass index (BMI) of less than 40;
  • willing to use only the study product, and Tramadol or Tylenol as a rescue pain medication over the course of their participation in the study;
  • willing and able to monitor blood glucose levels if diabetic;
  • willing to abstain from caffeine-containing drinks and food before coming into a study visit;
  • able to read and understand English and have the cognitive capacity to give consent;
  • willing to abstain from use of the following during participation in the study: prescription and over-the-counter non-steroidal anti-inflammatory medications, (e.g., aspirin, ibuprofen, Advil, Motrin, Nuprin, Naproxen, etc.); any dietary supplements (St. John's Wort, etc.); and, grapefruit and/or products containing it.

Exclusion Criteria:- cardiovascular disease, previous myocardial infarction, stent, coronary artery bypass graft (CABG), arrhythmia, high or low blood pressure;

  • recurrent stomach upset, or gastric or duodenal ulcers;
  • gallstones or gall bladder disease (cholelithiasis);
  • liver or kidney disease;
  • alcohol use of more than two drinks per day on a regular basis;
  • Coumadin or anti-platelet drug use;
  • at risk for respiratory depression, history of seizures, or taking drugs that reduce the seizure threshold or may increase the risk for development of serotonin syndrome;
  • pregnant or breast feeding, or intention to become pregnant during the study;
  • pronounced allergies, or known allergy to study product or corn starch (placebo);
  • have had an injection to treat OA within the past three months;
  • currently taking NSAIDs, unless they are willing to stop for a 1-week wash-out period;
  • currently on a selective serotonin reuptake inhibitor (SSRI) but are poorly stabilized, or have evidence of suicidal ideation and/or suicide attempts in the past year; and,
  • reported use during the 7 days prior to study drug administration of: prescription and over-the-counter medications (e.g., NSAIDs), and any dietary supplements; grapefruit and/or its products; and, St. John's Wort.

Sites / Locations

  • Univ of Missouri Health Care Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Enteric coated Devil's Claw

Non-enteric coated Devil's Claw

Arm Description

H. procumbens 100 mg in enteric coated capsules

H. procumbens 100 mg in non-enteric coated capsules

Outcomes

Primary Outcome Measures

Maximal concentration level of Devil's Claw metabolites, Cmax (ng/ml)
Blood will be drawn at predefined intervals following administration of one dose of study drug
Time to reach Cmax (h)
Blood will be drawn at predefined intervals following administration of one dose of study drug
Determination of terminal half-life of Devil's Claw, t 1/2 (h)
Blood will be drawn at predefined intervals following administration of one dose of study drug

Secondary Outcome Measures

Change in plasma levels of harpagoside
Blood will be drawn for Devil's Claws metabolites at Visit 2
Change in plasma levels of harpagide
Blood will be drawn for Devil's Claws metabolites at Visit 2
Change in plasma levels of verbascoside
Blood will be drawn for Devil's Claws metabolites at Visit 2
Change in levels of 8-p-coumarylharpagide
Blood will be drawn for Devil's Claws metabolites at Visit 2

Full Information

First Posted
August 16, 2018
Last Updated
May 19, 2022
Sponsor
University of Missouri-Columbia
search

1. Study Identification

Unique Protocol Identification Number
NCT03641248
Brief Title
Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract
Official Title
Study to Establish the Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract in Humans
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Recruitment was not possible due to COVID19.
Study Start Date
May 1, 2021 (Anticipated)
Primary Completion Date
July 31, 2021 (Anticipated)
Study Completion Date
August 31, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Missouri-Columbia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Study will define the bioavailability and short term pharmacokinetics of the principal secondary metabolites of a aqueous-ethanolic extract of H. procumbens in non-enteric and enteric capsules.
Detailed Description
The study(n = 12) will use a one-dose design to measure bioavailability and pharmacokinetic properties of an aqueous extract of H. procumbens containing 100mg harpagoside. Plasma levels of harpagoside, harpagide, verbascoside, and 8-p-coumarylharpagide will be measured for 24 hours with blood collections taken at timed intervals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Pharmacokinetic
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Enteric coated Devil's Claw
Arm Type
Experimental
Arm Description
H. procumbens 100 mg in enteric coated capsules
Arm Title
Non-enteric coated Devil's Claw
Arm Type
Active Comparator
Arm Description
H. procumbens 100 mg in non-enteric coated capsules
Intervention Type
Drug
Intervention Name(s)
Enteric coated Devil's Claw
Other Intervention Name(s)
Harpagophytum procumbens
Intervention Description
Enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Intervention Type
Drug
Intervention Name(s)
Non-enteric coated Devil's Claw
Other Intervention Name(s)
Harpagophytum procumbens
Intervention Description
Non-enteric coated capsules containing Devil's Claw extract with 100mg harpagoside
Primary Outcome Measure Information:
Title
Maximal concentration level of Devil's Claw metabolites, Cmax (ng/ml)
Description
Blood will be drawn at predefined intervals following administration of one dose of study drug
Time Frame
0.5 hour, 1 hour, 2 hours, 2.5 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 12 hours
Title
Time to reach Cmax (h)
Description
Blood will be drawn at predefined intervals following administration of one dose of study drug
Time Frame
0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours
Title
Determination of terminal half-life of Devil's Claw, t 1/2 (h)
Description
Blood will be drawn at predefined intervals following administration of one dose of study drug
Time Frame
0 hour, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours
Secondary Outcome Measure Information:
Title
Change in plasma levels of harpagoside
Description
Blood will be drawn for Devil's Claws metabolites at Visit 2
Time Frame
24 hours after dose of Devil's Claw
Title
Change in plasma levels of harpagide
Description
Blood will be drawn for Devil's Claws metabolites at Visit 2
Time Frame
24 hours after dose of Devil's Claw
Title
Change in plasma levels of verbascoside
Description
Blood will be drawn for Devil's Claws metabolites at Visit 2
Time Frame
24 hours after dose of Devil's Claw
Title
Change in levels of 8-p-coumarylharpagide
Description
Blood will be drawn for Devil's Claws metabolites at Visit 2
Time Frame
24 hours after dose of Devil's Claw

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:- adult (at least 18 years of age); diagnosed with knee osteoarthritis (OA) ; body mass index (BMI) of less than 40; willing to use only the study product, and Tramadol or Tylenol as a rescue pain medication over the course of their participation in the study; willing and able to monitor blood glucose levels if diabetic; willing to abstain from caffeine-containing drinks and food before coming into a study visit; able to read and understand English and have the cognitive capacity to give consent; willing to abstain from use of the following during participation in the study: prescription and over-the-counter non-steroidal anti-inflammatory medications, (e.g., aspirin, ibuprofen, Advil, Motrin, Nuprin, Naproxen, etc.); any dietary supplements (St. John's Wort, etc.); and, grapefruit and/or products containing it. Exclusion Criteria:- cardiovascular disease, previous myocardial infarction, stent, coronary artery bypass graft (CABG), arrhythmia, high or low blood pressure; recurrent stomach upset, or gastric or duodenal ulcers; gallstones or gall bladder disease (cholelithiasis); liver or kidney disease; alcohol use of more than two drinks per day on a regular basis; Coumadin or anti-platelet drug use; at risk for respiratory depression, history of seizures, or taking drugs that reduce the seizure threshold or may increase the risk for development of serotonin syndrome; pregnant or breast feeding, or intention to become pregnant during the study; pronounced allergies, or known allergy to study product or corn starch (placebo); have had an injection to treat OA within the past three months; currently taking NSAIDs, unless they are willing to stop for a 1-week wash-out period; currently on a selective serotonin reuptake inhibitor (SSRI) but are poorly stabilized, or have evidence of suicidal ideation and/or suicide attempts in the past year; and, reported use during the 7 days prior to study drug administration of: prescription and over-the-counter medications (e.g., NSAIDs), and any dietary supplements; grapefruit and/or its products; and, St. John's Wort.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Folk, PhD
Organizational Affiliation
Univ of Missouri
Official's Role
Principal Investigator
Facility Information:
Facility Name
Univ of Missouri Health Care Center
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65211
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Bioavailability and Pharmacokinetic Measures of H. Procumbens Extract

We'll reach out to this number within 24 hrs